1. Introduction {#sec1-metabolites-07-00014}
===============

Combination therapy has long been studied in the treatment of cancer, including ovarian cancer \[[@B1-metabolites-07-00014]\]. It is a logical approach, focusing on increasing the response and tolerability to treatment, while also decreasing resistance \[[@B2-metabolites-07-00014]\]. Unfortunately, it can be difficult to assess whether a particular combination will behave in a synergistic, additive, or antagonist fashion when used on a particular cancer patient. The only known way of determining their effectiveness is to identify specific measures, such as response rate, survival, or time to progression, and assess if or whether the new combination is able to achieve a significant improvement \[[@B2-metabolites-07-00014]\]. Combination therapy is essentially cooperative: each agent involved should have non-overlapping toxicities, different mechanisms of action with minimal cross-resistance, and individually proven in treatment by itself \[[@B2-metabolites-07-00014]\].

Several cancers, including ovarian cancer, have demonstrated resistance or reduced sensitivity to cisplatin treatment, leading to decreased time to disease progression, increased likelihood of relapse, and reduced efficacy upon re-treatment during relapse \[[@B3-metabolites-07-00014],[@B4-metabolites-07-00014]\]; cisplatin itself causes significant health problems, such as nephrotoxicity \[[@B5-metabolites-07-00014]\]. Ideally, cisplatin in combination with a drug that diminishes its negative effects while enhancing the therapeutic effects would decrease resistance or relapse while mitigating its negative effects. For example, cisplatin (or another platinum agent) in combination with taxanes (e.g., paclitaxel) is now regarded as standard chemotherapy in ovarian cancer, where the taxane enhances the tumour's radiosensitivity. Cisplatin and the adenovirus OBP-301 have also been shown to work synergistically \[[@B1-metabolites-07-00014]\].

Cisplatin shares cytotoxic synergy with bee venom \[[@B1-metabolites-07-00014]\]. Bee venom makes sense as a complement to cisplatin: it has protective effects in many areas of the body such as the blood and nerves \[[@B6-metabolites-07-00014]\]; it is able to inhibit cell growth in tumours \[[@B7-metabolites-07-00014]\]; and has even been examined and used in complementary treatments that are necessitated by the effects of chemotherapy, such as allodynia \[[@B8-metabolites-07-00014]\] and neuropathy \[[@B9-metabolites-07-00014]\]. Cisplatin in combination with bee venom has been successfully used against human cervical and laryngeal carcinoma cells, including their drug-resistant sublines \[[@B10-metabolites-07-00014]\], and human glioblastoma \[[@B11-metabolites-07-00014]\]. Several studies have found that phospholipase A~2~, another component of bee venom, not only mitigates the negative impact of cisplatin on kidneys \[[@B12-metabolites-07-00014]\], but also boosts regulatory T cell (Treg) numbers in the spleen and enhances Treg traffic to the kidneys following cisplatin exposure. This is important, as Tregs play a significant role in many mechanisms, including inflammation and autoimmunity suppression \[[@B4-metabolites-07-00014],[@B12-metabolites-07-00014],[@B13-metabolites-07-00014]\]. A significant bonus in this dynamic is that bee venom has no negative impact on the anti-cancer properties of the cisplatin \[[@B4-metabolites-07-00014]\], meaning it in no way diminishes the effect of the cisplatin treatment. This is critical; a combinatory agent which diminishes any positive effects of the primary treatment undermines its effectiveness overall. The effects that cisplatin and bee venom have together on ovarian cancer cells emerge from the synergistic relationship between the two agents \[[@B14-metabolites-07-00014]\]. Alizadehnohi et al. report that separately and together, the two agents induce apoptosis in human ovarian cancer cells; bee venom appears to enhance the cytotoxic impact of cisplatin \[[@B14-metabolites-07-00014]\]. It also appears that melittin provokes responses in cisplatin-sensitive cells which lead to decreasing levels of amino acids, which in turn affect the energy metabolism of the tumour \[[@B15-metabolites-07-00014]\].

In order to understand these effects and the metabolic changes that the cisplatin-melittin combination has on ovarian cancer cells, metabolomic investigations can be undertaken. Metabolomics in the context of oncology usefully focuses on diagnosis and prognosis, as well as on evaluating the effectiveness of therapy \[[@B16-metabolites-07-00014],[@B17-metabolites-07-00014]\]. For instance, one study employed nuclear magnetic resonance (^1^H-NMR) spectroscopy and was able to accurately separate serum metabolite profiles of three groups of patients: namely women with ovarian cancer, normal premenopausal women, and women with a benign ovarian disease \[[@B18-metabolites-07-00014]\]. In addition, LC-MS in combination with Biolog Microarray assays revealed that treatment of cisplatin-resistant and sensitive ovarian cancer cells with melittin distinctively altered their lipid profiles and their ability to metabolise certain carbon energy sources, \[[@B15-metabolites-07-00014]\]. NMR spectroscopy has also been used to produce and examine metabolic profiles in other cancers such as hepatocellular carcinoma \[[@B19-metabolites-07-00014]\].

In essence, the effects of the cytotoxic mechanisms of both cisplatin and melittin, together and separately, cause changes in cells which can be identified and measured through metabolomic analysis. The current study aimed to examine the metabolic effects of melittin in combination with cisplatin on A2780 and A2780CR human ovarian cancer cell lines using a LC-MS based metabolomics approach employing a ZIC-pHILIC column. Multivariate data analysis was performed based on PCA and OPLS-DA models constructed using the SIMCA-P software.

2. Results {#sec2-metabolites-07-00014}
==========

2.1. The Cytotoxicity of Melittin in Combination with Cisplatin {#sec2dot1-metabolites-07-00014}
---------------------------------------------------------------

The viabilities of the cisplatin-sensitive and cisplatin-resistant ovarian cancer cells (OCCs) (A2780 and A2780CR, respectively) treated with melittin or cisplatin were compared. Both single treatments exerted a concentration-dependent cytotoxic effect on A2780 and A2780CR cells ([Figure 1](#metabolites-07-00014-f001){ref-type="fig"}). The cisplatin mediated growth inhibition of the sensitive cell line (A2780) was significantly greater than that of the melittin over the concentration range of 1 to 8 μg/mL ([Figure 1](#metabolites-07-00014-f001){ref-type="fig"}A; *p* \< 0.05). However, the A2780CR cells, as expected, were more resistant to cisplatin than the A2780 cells ([Figure 1](#metabolites-07-00014-f001){ref-type="fig"}B). The 24 h half maximal inhibitory concentrations (IC~50~) of cisplatin in A2780CR and A2780 cells were 10.8 and 4.9 μg/mL, respectively. Melittin exhibited toxicity against both A2780CR and A2780 cells, with IC~50~ values of 4.5 and 6.8 μg/mL, respectively \[[@B15-metabolites-07-00014]\] ([Figures S1 and S2](#app1-metabolites-07-00014){ref-type="app"}). The cytotoxicity of melittin in combination with cisplatin against A2780 and A2780CR cells was studied by using an Alamar^®^ Blue assay \[[@B15-metabolites-07-00014]\]. The A2780 and A2780CR cells were treated for 24 h at various concentrations of melittin in combination with cisplatin. The percentage of surviving cells decreased in a dose-dependent manner in both cell lines. The cytotoxic effects of melittin in combination with cisplatin on A2780 and A2780CR cell lines are shown in [Figure 2](#metabolites-07-00014-f002){ref-type="fig"}A and [Figure 3](#metabolites-07-00014-f003){ref-type="fig"}A, respectively.

2.2. The Combination Index (CI) {#sec2dot2-metabolites-07-00014}
-------------------------------

In order to qualitatively evaluate whether the combination of melittin with cisplatin might cause synergistic cytotoxic effects, the value of CI, a commonly used evaluation index, was calculated. It has been proposed that CI values be interpreted as follows: \<0.1 very strong synergism, 0.1--0.3 strong synergism, 0.3--0.7 synergism, 0.7--0.9 moderate to slight synergism, 0.9--1.1 nearly additive, 1.1--1.45 slight to moderate antagonism, 1.45--3.3 antagonism, and \>3.3 strong to very strong antagonism \[[@B20-metabolites-07-00014]\].

The CI analyses showed that synergistic cytotoxic activity on A2780 cells occurred with the melittin + cisplatin combinations at concentrations of 5 + 2 (CI = 0.647) and 6 + 2 (CI = 0.512) μg/mL, and with the cisplatin+melittin combinations at concentrations of 4 + 3 (CI = 0.789) and 5 + 3 (CI = 0.711) μg/mL, respectively. However, the calculated CI was found to be \>1 in A2780 cells treated with the melittin + cisplatin combinations at concentrations of 3 + 2 (CI = 2.812) and 4 + 2 (CI = 1.259) μg/mL, and thus could represent an antagonistic effect ([Figure 2](#metabolites-07-00014-f002){ref-type="fig"}B). The melittin + cisplatin combinations had CI between 0.7--0.9, indicating a moderate to slight synergism relationship in A2780CR at 2 + 10 (CI = 0.888) and 5 + 10 (CI = 0.741) μg/mL, as shown in [Figure 3](#metabolites-07-00014-f003){ref-type="fig"}B. The CI value of melittin + cisplatin was 0.985 at concentrations of 3 + 10 μg/mL and 0.921 at concentrations of 4 + 10 μg/mL used to treat A2780CR, indicating a nearly additive effect. However, the calculated CI was found \>1 in A2780CR with the cisplatin+melittin combination at concentrations of 20 + 2 and 30 + 2 μg/mL and thus could represent an antagonism effect. The combination of melittin and cisplatin thus shows potential in the treatment of the resistant cells since there is no evidence of cross resistance against melittin which might be expected as a feature of multidrug resistance.

2.3. Metabolome Analysis {#sec2dot3-metabolites-07-00014}
------------------------

The metabolic effects of melittin in combination with cisplatin on ovarian cancer cells were assessed using an LC-MS based metabolomic approach. Univariate and multivariate statistical analyses were used to examine the effect of combination 1 (5 μg/mL of melittin + 2 μg/mL cisplatin) and combination 2 (2 μg/mL of melittin + 10 μg/mL cisplatin) on A2780 and A2780CR cells, respectively.

A clear separation of A2780 and A2780CR cells was achieved indicating unique metabolite profiles for the treated and control cells on the PCA and OPLS-DA scores plots at both treatment combinations ([Figure 4](#metabolites-07-00014-f004){ref-type="fig"}A,B, respectively). The pooled quality control (QC) samples injected at intervals in the analysis run to assess the precision of the measurements and confirm stability of the analytical method produced a single tight cluster in the center of the dataset ([Figure 4](#metabolites-07-00014-f004){ref-type="fig"}A), thus validating the analysis. The PCA model parameters and validation of the plot suggested a good model (four components, R2X (cum) = 0.918; Q2 (cum) = 0.856). There was also very clear separations between the treated and control A2780 and A2780CR cells in the OPLS-DA, a supervised model for classifying samples. The OPLS-DA model parameters and validation of the plot suggested a strong model (four components, R2X (cum) = 0.916, R2Y (cum) = 1, Q2 (cum) = 0.975), and the CV-ANOVA for this model was 1.28 × 10^−24^. Hierarchical clustering analysis (HCA) of the metabolomics data showed distinct separation between the control and treated samples ([Figure S3](#app1-metabolites-07-00014){ref-type="app"}).

There was a very clear separation of the treated versus untreated A2780 cells obtained by using the OPLS-DA model based on the significant metabolites ([Figure 5](#metabolites-07-00014-f005){ref-type="fig"}A). The model parameters and validation of the plot suggested a strong model (two components, R2X (cum) = 0.965, R2Y (cum) = 1, Q2 (cum) = 0.996, CV-ANOVA= 2.62 × 10^−6^). To test the validity, a receiver operator characteristic (ROC) curve and permutation test were also applied ([Figure S3](#app1-metabolites-07-00014){ref-type="app"}). The area under the curve (AUC) for the ROC curve is regarded as excellent when AUC \> 0.9. The OPLS-DA model classified the treated and untreated A2780 cells into two groups, and the AUC of the ROC for the groups were in the excellent to perfect classification.

In the case of the A2780CR cells, OPLS-DA models were also generated by comparing control and treated samples based on the significant metabolites ([Figure 5](#metabolites-07-00014-f005){ref-type="fig"}B). As in A2780 cells, a clear separation was also found between the treated and untreated A2780CR samples and the CV-ANOVA for this model was 8.42 × 10^−6^ (two components, R2X (cum) = 0.966, R2Y (cum) = 1, Q2 (cum) = 0.994). Furthermore, the validity of the ROC and permutation test showed that the constructed OPLS-DA model was valid ([Figures S4 and S5](#app1-metabolites-07-00014){ref-type="app"}).

For univariate statistical analysis of candidate specific biomarkers in ovarian cancer cells after exposure to the treatment combinations, the false discovery rate statistical test (FDR) was used to reduce the probability of false positive results \[[@B23-metabolites-07-00014]\]. Significant changes in the levels of various classes of metabolites, especially those in the mitochondrial TCA cycle, energy metabolism, and nucleotide and amino acids metabolism were observed as summarised in [Table 1](#metabolites-07-00014-t001){ref-type="table"}. The major impression is that the combination of melittin and cisplatin produces distinct metabolic profiles in both cell lines that are unlike those produced when either of the agents are used alone as previously reported \[[@B15-metabolites-07-00014],[@B24-metabolites-07-00014]\].

It can be observed that there is a strong reduction in the levels of metabolites involved in Krebs cycle and energy metabolism. Several metabolites in the TCA cycle, including citrate, 2-oxoglutarate, malate, and phosphoenolpyruvate were significantly decreased in both sensitive and resistant cells after treatment with the melittin + cisplatin combination. The treatment also reduced the levels of adenosine triphosphate (ATP) in both cell lines. It should be noted that the combination treatment had a stronger effect on ATP levels in the A2780 cells than in the A2780CR cells, although the treatments were not the same as they were based on cell sensitivities towards the two agents. There were also marked decreases in the levels of pentose phosphate pathway metabolites in both cell lines after the combination treatment. Moreover, there were important differences in the levels of purine and pyrimidine metabolites between the two cell lines after treatment with the combinations. With the exception of hypoxanthine and guanine (both purines) which were increased, the rest of these metabolites were significantly decreased by the combination treatment in both cell lines.

The most affected metabolites due to the combination treatment in both cell lines compared to the other pathways were involved in amino acid metabolism. In A2780 cells, the valine metabolite, 3-methyl-2-oxobutanoic acid, increased, while there were decreases in many amino acids related to arginine and proline metabolism. In A2780CR cells, significant increases were observed in the levels of S-adenosyl-L-methionine, 5′-methylthioadenosine, L-lysine, and L-serine.

3. Discussion {#sec3-metabolites-07-00014}
=============

Cisplatin is one of the most effective anticancer drugs currently used for treating many types of cancer, however, it comes with serious side effects. Combination therapy has been used in cancer treatment in order to increase therapeutic response and tolerability, and to decrease resistance \[[@B2-metabolites-07-00014]\].

The present study aimed to determine whether or not melittin, a cytotoxic peptide from bee venom, possesses a synergistic inhibitory effect in combination with cisplatin on A2780 and A2780CR cells. In addition, the study was intended to determine the metabolomics effects of the melittin + cisplatin combination treatment on the two cell lines which would corroborate any observed synergistic cytotoxic effects.

Cell viability assays using the Alamar^®^ Blue method confirmed the synergistic cytotoxic effects of melittin in combination with cisplatin at certain concentrations, although at other concentrations, antagonistic effects were observed. CI analysis of the cytotoxicity data showed that, on A2780 cells, the combinations had synergistic effects at 2 μg/mL of melittin plus either 5 or 6 μg/mL of cisplatin, respectively. In contrast, at melittin + cisplatin concentrations of 3 + 2 and 4 + 2 μg/mL, respectively, antagonistic effects were observed. Synergistic effects were observed in A2780CR cells when the melittin was combined with cisplatin at 2 + 10 and 5 + 10 μg/mL, while with a fixed concentration of melittin (2 μg/mL) and variable concentrations of cisplatin (20 and 30 μg/mL) in the combination, antagonist effects were observed. The CI analysis used the median effect equation of Chou and the combination index equation of Chou and Talalay to quantify synergism or antagonism at different concentrations, and to select the best pair of drugs to combine for potentially maximal antitumor efficacy \[[@B22-metabolites-07-00014],[@B25-metabolites-07-00014]\]. This method of analysis has been useful in identifying effective combinations of anticancer drugs \[[@B26-metabolites-07-00014],[@B27-metabolites-07-00014]\].

Recent studies have reported that components of bee venom may exert an anti-tumour effect on human ovarian cancer and that the venom has the potential for enhancing the cytotoxic effect of the antitumor agent cisplatin \[[@B14-metabolites-07-00014]\]. Different melittin + cisplatin mechanisms could interact to either reduce or increase anticancer efficacy, thus producing three possible effects: (1) Additive, when the combined effect is equal to the sum of individual effects; (2) Antagonistic, when the effect of one or both compounds is less than when they are applied together than when individually applied; (3) synergism, when the effect of combined substances is greater than the sum of the individual effects \[[@B24-metabolites-07-00014]\]. Our findings show that these effects can occur depending on the concentrations of melittin and cisplatin in the combination.

With respect to OCCs, several previous studies have analysed the metabolic responses of OCCs to various compounds \[[@B28-metabolites-07-00014],[@B29-metabolites-07-00014],[@B30-metabolites-07-00014]\]. Additionally, there have been some previous metabolomic studies on the comparison between the effects of cisplatin on squamous cancer cell lines sensitive and resistant to cisplatin \[[@B31-metabolites-07-00014]\], and the effects of docetaxel on ovarian cancer stem cells \[[@B30-metabolites-07-00014]\]. Our previous study employed a metabolomics approach to assess the effects of melittin monotherapy on OCCs that revealed significant changes in amino acid and carbohydrate metabolism \[[@B15-metabolites-07-00014]\]. In addition, clear differences were previously observed in the metabolomes of the untreated cells \[[@B15-metabolites-07-00014]\]. Although our study demonstrated profound metabolic changes in the cells after melittin monotherapy, there has been no metabolomics study to date that has comparatively profiled the metabolite composition of OCCs treated with a combination of melittin and cisplatin. A previous study suggested that combination therapy is more effective than monotherapy on cancer cells such as hepatocellular carcinoma \[[@B19-metabolites-07-00014]\]. In the current untargeted metabolomics study, metabolic profiles of A2780 and A2780CR cells treated with melittin + cisplatin combinations were assessed using a LC-MS based metabolomics approach, with OPLS-DA models displaying good separation between the experimental groups, high-quality goodness of fit (R^2^), and high-quality goodness of prediction (Q^2^).

The metabolomics analysis demonstrated distinct metabolic profiles for the treated A2780 and A2780CR cells, although the treatments were adjusted in accordance with cell sensitivities. Specifically, the concentrations of melittin and cisplatin used were chosen based on cytotoxicity assays and CI values for synergy to allow detection of a combination effect rather than to achieve a maximal anticancer effect. The most altered metabolites in A2780 and A2780CR cells could be categorised under amino acid, energy, carbohydrate, and nucleotide metabolism. Most of the altered metabolites participate in more than one pathway in significant ways, and the change in that one metabolite could have a resonating effect for other pathways.

There was a very clear effect of the combination treatment on the purine and pyrimidine pathways. This was very different from the metabolic shifts observed for melittin and cisplatin alone \[[@B15-metabolites-07-00014],[@B24-metabolites-07-00014]\], suggesting the combination has quite a different effect on cell metabolism. There was a very large increase in the levels of the adenine metabolite, hypoxanthine, and guanine in both cell lines. This possibly indicates that the combination of melittin with cisplatin is promoting greater adduct formation between cisplatin and DNA in comparison with the treatment with cisplatin alone, where there was no strong evidence for effects on the levels of DNA bases \[[@B24-metabolites-07-00014]\]. Adducts formed with cisplatin are mainly intra-strand crosslinks joining two guanine residues and to a lesser extent intra-strand links between guanine and adenine \[[@B32-metabolites-07-00014]\]. DNA is repaired by excision of damaged bases and this would correlate with largely increased levels of guanine and hypoxanthine, although this presumes that the cisplatin adduct somehow breaks down during the excision. The levels of the purine metabolites adenosine monophosphate (AMP), adenosine diphosphate (ADP), and guanosine triphosphate (GTP) were decreased in both cell lines by the combination treatment. In a previous study, it was found that FK866, a small molecule inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), caused significant metabolic changes in purine metabolism in ovarian cancer and colorectal cancer cells \[[@B30-metabolites-07-00014]\]. Moreover, Zhou et al. described a study in hepatocellular carcinoma (HepG2 cells) that showed that high-dose treatment with sorafenib, an oral multikinase inhibitor, affects purine metabolism with significant decreases in GTP levels \[[@B33-metabolites-07-00014]\]. Despite the profound dose-dependent metabolic changes in HepG2 cells induced by sorafenib monotherapy, Zhou et al. showed that everolimus, another anticancer agent, in combination with first-line sorafenib therapy results in more pronounced metabolic changes to pyruvate, amino acid, methane, glyoxylate, and dicarboxylate, and glycolysis or gluconeogenesis in hepatocellular carcinoma cells \[[@B33-metabolites-07-00014]\]. Other than purine metabolite changes, consistent variations were observed for pyrimidine metabolism. The levels of pyrimidine metabolites such as orotate, dihydrothymine, dihydrouracil, and uridine triphosphate (UTP) were reduced in both cell lines after exposure to the melittin + cisplatin combinations. The reason for the decrease in pyrimidine metabolites is not clear. Normally DNA damage might be associated with increased levels of dihydrothymine which is produced by excision of damaged thymine residues from DNA.

There were many altered metabolites belonging to several pathways for amino acid metabolism. Most of the metabolites grouped under the arginine and proline pathways were reduced in sensitive cells after the combination treatments; while the arginine metabolite was non-significantly altered in resistant cells. Similarly, our previous study examined the effect of melittin on A2780 and A2780CR cells which showed that the level of arginine was downregulated in cisplatin sensitive cells compared with resistant cells \[[@B15-metabolites-07-00014]\]. A number of studies have reported that arginine deficiency enhances apoptosis in different cell lines including human lymphoblastic cell lines \[[@B34-metabolites-07-00014]\], mesothelioma cells \[[@B35-metabolites-07-00014]\], and melanoma cell lines \[[@B36-metabolites-07-00014]\]. Some human cancers, such as melanoma and hepatocellular carcinoma \[[@B37-metabolites-07-00014]\], do not express arginosuccinase synthase and therefore are unable to synthesise arginine from citrulline \[[@B38-metabolites-07-00014]\]. A recent study observed that ovarian carcinoma SKOV3 cells under arginine deprivation showed increased sensitivity to treatment with paclitaxel, a chemotherapy drug used to treat cancers, at low doses. In this context, it is to be noted that paclitaxel is a disruptor of the cytoskeleton and negatively impacts on the autophagosome-lysosome fusion step \[[@B39-metabolites-07-00014]\]. A previous study suggested that combinational treatment based on arginine deprivation and an autophagy inhibitor (for example chloroquine, a known nontoxic antimalarial drug) can potentially be applied as a second line treatment for a subset of ovarian carcinomas deficient in argininosuccinate synthetase \[[@B39-metabolites-07-00014]\]. It was also observed that the development of chemoresistance to platinum compounds in ovarian carcinomas leads to collateral appearance of arginine auxotrophy due to the downregulation of argininosuccinate synthetase \[[@B40-metabolites-07-00014]\]. The exact mechanism whereby deficiency arginine biosynthesis confers resistance remains unclear.

There was a strong effect of the combination treatment on cellular cysteine and glutathione metabolism; S-glutathionyl-L-cysteine, 3-sulfino-L-alanine, glutathione, L-cysteinylglycine, and L-cystathionine were all lower in cisplatin sensitive cells compared with resistant cells after being treated with the combinations. In a previous study, it was found that the level of glutathione was higher in resistant cells (A2780-CP20) than in sensitive cells (A2780) \[[@B41-metabolites-07-00014]\]. This finding resembles the current results in which the level of glutathione was higher in resistant cells than sensitive cells following combination treatment. Two of the main reasons for platinum resistance in OCCs are the p53 mutation and drug-induced increases in intracellular glutathione concentration. A study by Mohell et al. showed that methylene quinuclidinone (MQ), in addition to binding to cysteine residues in p53, also binds to glutathione, decreasing intracellular glutathione levels in OCCs \[[@B42-metabolites-07-00014]\]. Therefore, it is possible that the combination promotes greater binding of cisplatin to glutathione thus depleting its levels which occurs to a greater extent in the sensitive cells. Mohell et al. also observed that combination effects of APR-246 (which is a prodrug that is converted to the active compound MQ) with doxorubicin were the cause of a DNA damage response, including activation of the p53 pathway leading to apoptosis \[[@B42-metabolites-07-00014]\]. Moreover, recent metabolomics based studies in OCCs have demonstrated that gossypol decreases cellular levels of GSH and induces apoptosis through oxidative stress \[[@B30-metabolites-07-00014]\]. In our previous study it was observed that the levels of GSH were no different between resistant and sensitive cells. However, in the current study GSH is depleted by the combination treatment to a much greater extent in the sensitive cells. The depletion appears to be related to the ability of the cells to synthesise GSH. Although there is no difference between the cysteine levels in the two cell lines, there are marked differences in key intermediates which can be used to synthesise both cysteine and GSH including glycine, serine, cystathionine, and glutathione cysteine. There are also lower levels of S-adenosylmethionine in the treated sensitive cells which is a source of homocysteine which is also a precursor of cysteine.

Increased serine biosynthesis is one of many metabolic changes that have been reported in cancer cells \[[@B43-metabolites-07-00014],[@B44-metabolites-07-00014]\], and serine is a central node for the biosynthesis of many molecules such as glycine and cysteine \[[@B45-metabolites-07-00014]\]. High levels of serine in cancer cells have been linked to increased rates of cell proliferation \[[@B46-metabolites-07-00014]\]. The level of serine was increased in resistant cells following the combination treatment. In contrast, treatment of the sensitive cells with the combination resulted in a decrease of serine within the cells and a further lowering of the nonessential amino acid glycine. Glycine is incorporated directly into purine nucleotide bases and into GSH. The conversion of serine to glycine, catalysed by serine hydroxymethyltransferase (SHMT), donates a one-carbon unit to tetrahydrofolate to produce 5, 10-methylenetetrahydrofolate (CH~2~-THF). CH~2~-THF is used in thymidine synthesis and is a precursor of other folate species that contribute to purine synthesis \[[@B46-metabolites-07-00014]\]. The difference in OCCs could be reflected at the cellular level in terms of differences in the metabolite profiles. Serine is required for a number of biosynthetic and signalling pathways, including the production of phospholipids such as sphingolipids and phosphatidylserine \[[@B46-metabolites-07-00014]\]. Previous studies have shown that serine biosynthesis appears to be part of an adaptive response to oxidative stress \[[@B47-metabolites-07-00014]\]. The tumour suppressor p53 is emerging as an important regulator of cellular metabolism. P53 is a key player in the cellular response to stress in the form of numerous challenges, including DNA damage, hypoxia, and oncogene activation \[[@B48-metabolites-07-00014]\]. Cells lacking p53 fail to respond to serine starvation due to oxidative stress, which leads to reduced viability and severely impaired proliferation \[[@B49-metabolites-07-00014]\].

The level of ATP was found to be reduced in both cell lines after the combination treatment. ATP was found to be more reduced in both cell lines when treated with the combinations compared with the results observed previously with melittin monotherapy \[[@B15-metabolites-07-00014]\]. It is known that glycolysis provides ATP and energy in most cell types, but cancer cells extensively use glycolysis to sustain anabolism, which is necessary for tumour growth \[[@B50-metabolites-07-00014]\]. We found that the combinations inhibited glycolysis in both cell lines as indicated by lower levels of fructose bisphosphate and phosphopyruvate. In addition, several TCA cycle intermediates were lowered. Cell death can be executed by different mechanisms, including apoptosis, autophagy, necrosis, or combinations of these processes. Although different cell death mechanisms are unique in their molecular signalling cascades, one molecule is involved in the processes that mediates all types of cell death; ATP. During late-stage apoptosis, ATP levels sharply drop, mostly because of the loss of mitochondrial function and consumption by ATP-dependent proteases. In autophagy, a rescue process of self-degradation to compensate for energy paucity occurs, that also features ATP insufficiency prior to cell death \[[@B50-metabolites-07-00014],[@B51-metabolites-07-00014]\]. During necrosis, depletion of ATP precedes mitochondrial permeability changes \[[@B52-metabolites-07-00014]\]. The fact that ATP deprivation occurs in all types of cell death suggests that energy metabolism may play a critical role in the survival of cancer cells under stress. Thus, it could be possible that the A2780 cells may be undergoing late-stage apoptosis cell death in response to the combination treatment whereas the A2780CR may be undergoing early-stage apoptosis cell death. In our study, we found that combination treatment probably inhibited glycolysis in A2780 cells by depletion of NAD^+^. Moreover, the level of NAD^+^ was found to be decreased in A2780CR cells after combination treatment. It appears that the combinations had more impact on the oxidative phosphorylation pathway in both cell lines in comparison with melittin as a single treatment \[[@B15-metabolites-07-00014]\]. The inhibition of NAMPT leads to suppression of tumour cell growth and induction of apoptosis due to NAD^+^ depletion \[[@B53-metabolites-07-00014]\]. NAMPT represents a promising therapeutic target for the development of potential novel cancer drugs \[[@B54-metabolites-07-00014],[@B55-metabolites-07-00014]\]. In most cancer cells, poly (ADP-ribose) polymerase is activated due to DNA damage and cell death induced by oxidative stress \[[@B56-metabolites-07-00014],[@B57-metabolites-07-00014]\]. Therefore, NAMPT inhibition leads to attenuation of glycolysis, resulting in further alteration of the carbohydrate metabolism in the cells \[[@B53-metabolites-07-00014]\].

4. Materials and Methods {#sec4-metabolites-07-00014}
========================

4.1. Cell Lines and Cultures {#sec4dot1-metabolites-07-00014}
----------------------------

The cisplatin-sensitive (A2780) and resistant (A2780CR) human ovarian carcinoma cells were obtained from ECACC (Porton Down, Salisbury, UK) and maintained at 75 × 10^4^ cells/mL in RPMI 1640 medium (Lonza, Verviers, Belgium) supplemented with 1% (v/v) [l]{.smallcaps}-glutamine (Invitrogen, Paisley, UK), 100 IU/mL/100 μg/mL penicillin/streptomycin (Invitrogen, Paisley, UK), and 10% (v/v) foetal bovine serum (FBS) (Life Technologies, Carlsbad, CA, USA). In addition, the cultures for the A2780CR cells contained 3 μg/mL of cisplatinum (Tocris Bioscience, Bristol, UK) in the first three passages. Sub-confluent cultures were split by trypsinisation every 4--5 days and maintained at 37 °C in a humidified atmosphere saturated with 5% CO~2~.

4.2. Cell Viability Assay {#sec4dot2-metabolites-07-00014}
-------------------------

Cisplatin was purchased from Tocris Bioscience (Bristol, UK) and was dissolved in sterile water with gentle warming according to the manufacturer's instructions. Melittin was purified from bee venom (supplied by Beesen Co. Ltd., Dae Jeon, Korea) by reversed phase liquid chromatography \[[@B58-metabolites-07-00014]\] and reconstituted in sterile water to form a stock solution of 1 mg/mL before storage at −20 °C until required. Cell viability was assessed by an Alamar^®^ Blue cell assay (Thermo Fisher Scientific, Loughborough, UK), as previously described \[[@B15-metabolites-07-00014]\].

To test the synergistic cytotoxic effect, experiments were performed with A2780 and A2780CR cell lines using various combinations of melittin with cisplatin in medium, to assess possible synergistic/additive effects. Both A2780 and A2780CR cells were seeded at 1 × 10^4^ cells/well in 96-well plates (Corning^®^, Sigma-Aldrich, Poole, UK) and incubated at 37 °C and 5% CO~2~ in a humidified atmosphere for 24 h. For the A2780 cell line, 3, 4, 5, and 6 μg/mL of melittin was combined with 2 μg/mL of cisplatin and 3, 4, and 5 μg/mL of cisplatin was combined with 3 μg/mL of melittin. For the A2780CR cell line, 2, 3, 4 and 5 μg/mL of melittin was combined with 10 μg/mL of cisplatin and 20 and 30 μg/mL of cisplatin was combined with 2 μg/mL of melittin. Twenty hours after drug treatment, AB was added at a final concentration of 10% (v/v) and the resultant mixture was incubated for a further 4 h at 37 °C and 5% CO~2~. Then, the plates were read at an excitation wavelength of 560 nm and the emission at 590 nm was recorded on a SpectraMax M3 microplate reader (Molecular Devices, Sunnyvale, CA, USA). All experiments were performed in triplicate.

4.3. Calculation of CI {#sec4dot3-metabolites-07-00014}
----------------------

The specific interaction between melittin and cisplatin on A2780 and A2780CR cancer cell lines was evaluated by the CI analysis. Drug combination synergy was performed using CompuSyn software \[[@B59-metabolites-07-00014]\]. CI values and CI-Fa plot (plot representing CI versus Fa, the fraction affected by a particular dose) were calculated by CompuSyn program (Compusyn Inc., Paramus, NJ, USA). All experiments were repeated at least three times.

4.4. Statistical Analysis {#sec4dot4-metabolites-07-00014}
-------------------------

GraphPad Prism for Windows (version 5.00, GraphPad Software, San Diego, CA, USA) was employed to produce dose-response curves by performing nonlinear regression analysis of the cell viability data. The mean IC~50~ values were calculated from at least three measurements of independent experiments (*n* = 3).

4.5. Determination of the Effect of Melittin in Combination with Cisplatin on Cell Metabolomes {#sec4dot5-metabolites-07-00014}
----------------------------------------------------------------------------------------------

The A2780 cell line was treated with the combination of melittin and cisplatin at concentrations of 5 and 2 μg/mL, respectively, for 24 h (*n* = 5). The A2780CR cells were treated with the combination of melittin and cisplatin at concentrations of 2 and 10 μg/mL, respectively, for 24 h (*n* = 5). The cells were seeded at 75 × 10^4^ cells/mL in T-25 cell culture flasks and incubated for 1 doubling time (48 h) before treatment with the combinations and incubation for an additional 24 h. After the treatment, the medium was removed and the cells were washed twice with 3 mL of phosphate-buffered saline (PBS) at 37 °C before lysis. Cell lysates were prepared by extraction with ice cold methanol:acetonitrile:water (50:30:20) (1 mL per 2 × 10^6^ cells). The cells were scraped and cell lysates mixed on a Thermo mixer at 1440 rotations per minute (r.p.m.) for 12 min at 4 °C, before being centrifuged at 13500 r.p.m. for 15 min at 0 °C. The supernatants were collected and transferred into HPLC vials for LC-MS analysis. During the analysis, the temperature of the autosampler was maintained at 4 °C. Mixtures of standard metabolites (Sigma-Aldrich, Poole, UK) and the pooled quality control (QC) sample were injected in each analysis run in order to facilitate identification and to evaluate the stability and reproducibility of the analytical method. The pooled QC sample was obtained by taking equal aliquots from all the samples and placing them into the same HPLC vial.

4.6. LC-MS Conditions {#sec4dot6-metabolites-07-00014}
---------------------

Liquid chromatographic separation was carried out on an Accela HPLC system interfaced to an Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) using a hydrophilic interaction liquid chromatography (HILIC) column (ZIC-pHILIC, 150 × 4.6 mm, 5 μm particle size) supplied by Hichrom Ltd. (Reading, UK). The method was reported previously \[[@B60-metabolites-07-00014]\]. Briefly, the mobile phase for ZIC-pHILIC consisted of 20 mM ammonium carbonate (Sigma-Aldrich, Poole, UK) in water purified by Direct-Q3 Ultrapure water purification system (Millipore, UK) at pH 9.2 (solvent A) and acetonitrile (Sigma-Aldrich, Poole, UK) (solvent B) at a flow rate of 0.3 mL/min. The elution gradient was an A:B ratio of 20:80 at 0 min, 80:20 at 30 min, 92:8 at 35 min, and finally 20:80 at 45 min.

4.7. Data Extraction and Analysis {#sec4dot7-metabolites-07-00014}
---------------------------------

Data extraction for each of the samples was carried out by MZmine-2.10 software (mzmine.github.io/) using identical parameters for peak detection, deconvolution, deisotoping, alignment, filtering, and gap filling in order to make multiple data files comparable \[[@B23-metabolites-07-00014]\]. The extracted ions, with their corresponding m/z values and retention times, were pasted into an Excel macro of the most common metabolites prepared in--house to facilitate identification, and a library search was also carried out against accurate mass data of the metabolites in the Human Metabolome, Kyoto Encyclopedia of Genes and Genomes, and Metlin databases. The lists of the metabolites obtained from these searches were then carefully evaluated manually by considering the quality of their peaks and their retention time match to the standard metabolite mixtures run in the same sequence. The MS data were log~2~-transformed and mean-centred with unit variance scaling for statistical analysis. Statistical analyses were performed using both univariate and multivariate approaches. The *p*-values from univariate analysis were adjusted using the FDR control and differences in the levels (or peak areas) of the metabolites between treated and control cells were considered significant at *p* \< 0.05. MetaboAnalyst^®^, a web-based metabolomic data processing tool \[[@B60-metabolites-07-00014]\], was used for supporting fold-change analysis, and *t*-tests. SIMCA-P software version 14.0 (Umetrics, Crewe, UK) was also used for multivariate analysis of the metabolite data with Pareto scaling prior to modelling with PCA and OPLS-DA. OPLS-DA models were validated based on multiple correlation coefficient (*R*^2^) and cross-validated R^2^ (*Q*^2^) in cross-validation and permutation tests.

5. Conclusions {#sec5-metabolites-07-00014}
==============

Based on the results presented, a metabolic signature for the cisplatin and melittin combination treatment for A2780 and A2780CR OCCs is proposed. Melittin and cisplatin together have different metabolic effects on these cells compared to melittin alone, which preferentially affects fatty acids, amino acids, and TCA cycle intermediates. The most significantly affected metabolites due to the melittin + cisplatin combination treatment in both cell lines were in the TCA cycle, oxidative phosphorylation, purine and pyrimidine metabolism, and arginine/proline pathways. This distinct mechanism of action of the melittin + cisplatin combination may provide a new paradigm for overcoming chemoresistance in ovarian cancer therapy. Our results provide rationale for the ongoing study of melittin in combination with cisplatin that could produce improved therapy for platinum resistance in ovarian cancer.
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![Examination of cell viability after treatment with either cisplatin or melittin alone with various concentrations on (**A**) A2780 and (**B**) A2780CR cell lines. \* Significantly different from zero. concentration at \<0.05; \*\*\* Significant at \<0.001.](metabolites-07-00014-g001){#metabolites-07-00014-f001}

![Effects of melittin in combination with cisplatin on (**A**) cell viability of A2780 cell lines and (**B**) combination index. (**A**) The A2780 cells were treated with various concentrations of the melittin + cisplatin combination for 24 h. Bar graphs represent mean ± SD values. (**B**) Combination index (CI) analysis was generated using the method of Chou and Talalay \[[@B21-metabolites-07-00014],[@B22-metabolites-07-00014]\] to determine the extent of synergy, if any, for the melittin + cisplatin combination on A2780 cell lines.](metabolites-07-00014-g002){#metabolites-07-00014-f002}

![Effect of melittin in combination with cisplatin on (**A**) cell viability of A2780CR cell lines and (**B**) combination index. (**A**) The A2780CR cells were treated with various concentrations of the melittin + cisplatin combination for 24 h. Bar graphs represent mean ± SD values. (**B**) Combination index (CI) analysis was generated using the method of Chou and Talalay \[[@B21-metabolites-07-00014],[@B22-metabolites-07-00014]\] to determine the extent of synergy, if any, for the melittin + cisplatin combination on A2780CR cell lines.](metabolites-07-00014-g003){#metabolites-07-00014-f003}

![(**A**) Principal components analysis (PCA) vs. (**B**) Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA). PCA and OPLS-DA scores plot generated from PCA and OPLS-DA using LC-MS normalised data of cells after exposure to the combination (melittin + cisplatin) and controls of A2780 and A2780CR cell lines. A2780-treated cells at 5 μg/mL melittin + 2 μg/mL cisplatin (SOS); untreated A2780 cells (C); A2780CR-treated cells at 2 μg/mL melittin + 10 μg/mL cisplatin (SOR); untreated A2780CR (CR); pooled quality control (QC) samples (P).](metabolites-07-00014-g004){#metabolites-07-00014-f004}

![OPLS-DA score plot of (**A**) A2780 cells and (**B**) A2780CR before and after treatment with melittin + cisplatin respectively. Separation of the treated and untreated cells in both cell lines in the model suggests that there are significant metabolite differences induced by treatment in both cell lines. The metabolites responsible for the observed separation are shown in [Table 1](#metabolites-07-00014-t001){ref-type="table"}.](metabolites-07-00014-g005){#metabolites-07-00014-f005}
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###### 

Metabolites significantly altered by treatment with melittin in combination with cisplatin at 5 μg/mL melittin + 2 μg/mL cisplatin on A2780 and at 2 μg/mL melittin + 10 μg/mL cisplatin on A2780CR.

  m/z                                           RT (min)   Metabolites                                SR/CR     SS/C              
  --------------------------------------------- ---------- ------------------------------------------ --------- ------- --------- --------
  **Citrate cycle (TCA cycle)/glycolysis**                                                                                        
  338.989                                       18.1       \* D-Fructose 1,6-bisphosphate             \<0.001   0.278   \<0.001   0.246
  115.004                                       16.0       \* Fumarate                                \<0.001   0.227   \<0.01    0.402
  133.014                                       16.1       \* (S)-Malate                              \<0.001   0.218   \<0.001   0.062
  145.014                                       15.7       \* 2-Oxoglutarate                          \<0.001   0.324   \<0.001   0.048
  191.02                                        18.1       \* Citrate                                 \<0.001   0.588   \<0.001   0.172
  173.009                                       17.9       \* cis-Aconitate                           \<0.001   0.490   \<0.001   0.072
  166.975                                       17.5       \* Phosphoenolpyruvate                     \<0.001   0.344   \<0.05    0.082
  **Oxidative phosphorylation**                                                                                                   
  664.116                                       14.2       \* NAD+                                    \<0.001   0.294   \<0.001   0.067
  508.003                                       16.2       \* ATP                                     \<0.001   0.362   \<0.001   0.073
  **Glycine/Serine/Cysteine and Glutathione**                                                                                     
  241.031                                       16.3       \* L-Cystine                               ns        1.739   ns        1.832
  427.095                                       17.1       S-Glutathionyl-L-cysteine                  ns        0.750   \<0.001   0.218
  152.002                                       14.6       3-Sulfino-L-alanine                        ns        0.706   \<0.001   0.139
  308.091                                       14.5       \* Glutathione (GSH)                       \<0.001   0.562   \<0.001   0.092
  179.048                                       14.4       L- Cysteinylglycine (Cys-Gly)              \<0.001   0.521   \<0.001   0.067
  223.074                                       17.1       \* L-Cystathionine                         \<0.001   0.438   \<0.001   0.004
  76.0394                                       15.7       \* Glycine                                 ns        1.050   \<0.001   0.142
  116.035                                       10.8       L-2-Amino-3-oxobutanoic acid               \<0.001   0.319   \<0.001   0.317
  106.050                                       15.8       \* L-Serine                                \<0.001   7.112   \<0.001   0.420
  **Pentose phosphate pathway**                                                                                                   
  195.051                                       13.7       \* D-Gluconic acid                         \<0.001   0.147   \<0.001   0.093
  308.978                                       16.5       D-Ribose 1,5-bisphosphate                  \<0.001   0.259   \<0.001   0.124
  149.046                                       11.9       \* D-Ribose                                \<0.001   0.222   \<0.001   0.285
  229.012                                       15.8       \* D-Ribose 5-phosphate                    \<0.001   0.545   \<0.001   0.131
  **Lysine biosynthesis**                                                                                                         
  170.046                                       14.3       2,3,4,5-Tetrahydrodipicolinate             \<0.001   0.245   \<0.001   0.112
  147.113                                       24.3       \* L-Lysine                                \<0.001   1.966   ns        0.724
  162.112                                       13.3       \* L-Carnitine                             \<0.001   0.508   \<0.001   0.135
  243.074                                       17.2       5-Phosphonooxy-L-lysine                    \<0.001   0.303   \<0.001   0.006
  128.071                                       15.5       2,3,4,5-Tetrahydropyridine-2-carboxylate   \<0.001   0.433   \<0.001   0.271
  **Purine metabolism**                                                                                                           
  137.046                                       10.2       \* Hypoxanthine                            \<0.001   16.99   \<0.01    7.87
  152.056                                       12.4       \* Guanine                                 \<0.001   13.19   \<0.01    102.21
  348.07                                        13.8       \* AMP                                     \<0.001   0.372   \<0.001   0.190
  428.036                                       15.0       \* ADP                                     \<0.001   0.376   \<0.001   0.163
  442.018                                       17.8       GDP                                        \<0.001   0.509   ns        0.104
  521.984                                       18.9       \* GTP                                     \<0.001   0.442   \<0.001   0.079
  426.013                                       16.9       Adenylyl sulfate                           \<0.001   0.271   \<0.01    0.014
  **Pyrimidine metabolism**                                                                                                       
  155.01                                        10.3       \* Orotate                                 \<0.001   0.218   \<0.001   0.050
  129.066                                       14.8       5,6-Dihydrothymine                         \<0.001   0.326   \<0.001   0.120
  480.982                                       15.8       dTTP                                       \<0.001   0.337   \<0.001   0.347
  175.036                                       16.8       N-Carbamoyl-L-aspartate                    \<0.001   0.036   \<0.001   0.017
  115.05                                        14.7       5,6-Dihydrouracil                          \<0.001   0.383   \<0.001   0.079
  402.995                                       16.4       \* UDP                                     \<0.001   0.485   \<0.001   0.035
  484.975                                       17.6       \* UTP                                     \<0.001   0.465   \<0.001   0.059
  323.029                                       15.2       \* UMP                                     ns        1.195   \<0.001   0.282
  **Arginine/Proline/Glutamate/Methionine**                                                                                       
  188.057                                       14.3       N-Acetyl-L-glutamate                       \<0.001   0.241   \<0.001   0.029
  176.103                                       15.8       \* L-Citrulline                            \<0.001   0.521   \<0.001   0.189
  173.104                                       25.8       \* L-Arginine                              ns        1.161   \<0.001   0.379
  130.051                                       14.5       L-Glutamate-5-semialdehyde                 \<0.001   0.538   \<0.001   0.235
  116.071                                       12.8       \* L-Proline                               \<0.001   0.568   \<0.001   0.228
  399.144                                       16.3       \* S-Adenosyl-L-methionine                 \<0.001   2.005   \<0.001   0.115
  298.096                                       6.4        \* 5′-Methylthioadenosine                  \<0.05    2.016   \<0.001   0.158
  146.093                                       15.1       \* 4-Guanidinobutanoate                    \<0.001   0.325   \<0.001   0.055
  291.129                                       16.8       N-(L-Arginino) succinate                   \<0.001   0.260   \<0.001   0.010
  247.14                                        14.2       N~2~-(D-1-Carboxyethyl)-L-arginine         \<0.001   0.170   \<0.001   0.010
  174.087                                       15.3       5-Guanidino-2 oxopentanoate                \<0.001   0.680   \<0.001   0.058
  132.077                                       14.7       \* Creatine                                \<0.001   0.403   \<0.001   0.075
  210.029                                       15.2       \* Phosphocreatine                         \<0.001   0.422   \<0.001   0.051
  **Miscellaneous**                                                                                                               
  110.027                                       14.9       Hypotaurine                                \<0.001   0.139   \<0.001   0.009
  115.04                                        8.2        3-Methyl-2-oxobutanoic acid                \<0.001   0.191   \<0.05    5.604
  166.053                                       13.4       L-Methionine S-oxide                       \<0.01    0.470   \<0.001   0.250
  218.067                                       13.9       O-Succinyl-L-homoserine                    \<0.001   0.082   \<0.001   0.011
  181.051                                       9.0        3-(4-Hydroxyphenyl)lactate                 \<0.001   0.656   \<0.001   0.087
  204.123                                       11.1       \* O-Acetylcarnitine                       \<0.001   0.137   \<0.001   0.021
  176.056                                       10.3       4-Hydroxy-4-methylglutamate                ns        1.911   \<0.001   0.022
  159.076                                       15.8       4-Methylene-L-glutamine                    \<0.001   0.607   ns        0.258
  175.025                                       14.4       \* Ascorbate                               \<0.001   0.067   \<0.001   0.024
  165.041                                       13.0       L-Arabinonate                              \<0.001   0.372   \<0.001   0.166
  179.056                                       17.1       Hexose                                     \<0.05    0.670   \<0.05    0.334

RT: min; SR: combination 2 treated A2780CR; CR: control A2780CR; SS: combination 1 treated A2780; C: control A2780; ns: non-significant. \* Retention time matches standard.
